ATE207761T1 - Insulin formulierung - Google Patents

Insulin formulierung

Info

Publication number
ATE207761T1
ATE207761T1 AT94305883T AT94305883T ATE207761T1 AT E207761 T1 ATE207761 T1 AT E207761T1 AT 94305883 T AT94305883 T AT 94305883T AT 94305883 T AT94305883 T AT 94305883T AT E207761 T1 ATE207761 T1 AT E207761T1
Authority
AT
Austria
Prior art keywords
insulin
formulation
zinc
total
present
Prior art date
Application number
AT94305883T
Other languages
English (en)
Inventor
James Arthur Hoffmann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE207761T1 publication Critical patent/ATE207761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94305883T 1993-08-13 1994-08-09 Insulin formulierung ATE207761T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (1)

Publication Number Publication Date
ATE207761T1 true ATE207761T1 (de) 2001-11-15

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94305883T ATE207761T1 (de) 1993-08-13 1994-08-09 Insulin formulierung

Country Status (27)

Country Link
US (1) US5534488A (de)
EP (1) EP0646379B1 (de)
JP (1) JPH07149660A (de)
KR (1) KR950005324A (de)
CN (1) CN1109364A (de)
AT (1) ATE207761T1 (de)
AU (1) AU674975B2 (de)
BR (1) BR9403204A (de)
CA (1) CA2129763A1 (de)
CO (1) CO4230235A1 (de)
CZ (1) CZ193794A3 (de)
DE (1) DE69428860T2 (de)
DK (1) DK0646379T3 (de)
ES (1) ES2164691T3 (de)
HU (1) HUT67853A (de)
IL (1) IL110581A0 (de)
NO (1) NO942959L (de)
NZ (1) NZ264197A (de)
PE (1) PE14495A1 (de)
PH (1) PH30757A (de)
PL (1) PL177002B1 (de)
PT (1) PT646379E (de)
RU (1) RU2135205C1 (de)
TW (1) TW326394B (de)
UA (1) UA27874C2 (de)
YU (1) YU50494A (de)
ZA (1) ZA945939B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
EP1396272A1 (de) * 1997-12-23 2004-03-10 Eli Lilly & Company Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
EP1196446A1 (de) * 1999-06-29 2002-04-17 Eli Lilly And Company Protaminfreie, unlösliche zusammensetzungen von acyliertem insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
AU4935701A (en) * 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
WO2003057650A2 (en) 2002-01-09 2003-07-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
WO2002029833A1 (en) * 2000-10-06 2002-04-11 The Adviser - Defence Research & Development Organisation A magneto sensitive fluid composition and a process for preparation thereof
US6875368B2 (en) * 2000-11-29 2005-04-05 The Adviser Defence Research And Development Organisation, Ministry Of Defence, Government Of India Magnetorheological fluid composition and a process for preparation thereof
DE60217066T4 (de) * 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
RU2251426C1 (ru) * 2003-09-18 2005-05-10 Цыганков Владимир Владимирович Способ получения инсулина из природного источника и инсулин
EP1711220A1 (de) * 2004-01-16 2006-10-18 Biodel, Inc. Sublinguale arzneimittelabgabevorrichtung
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2106790B1 (de) * 2004-03-12 2012-10-24 Biodel, Inc. Schnell wirkende Arzneimittelabgabezusammensetzungen
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
JP4903690B2 (ja) 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク N−[8−(2−ヒドリキシベンゾイル)アミノ]カプリル酸一ナトリウムの結晶多形体
AU2005249410A1 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
RU2288000C1 (ru) * 2005-04-27 2006-11-27 Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН) Раствор инсулина для перорального введения
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
WO2009089181A1 (en) * 2008-01-04 2009-07-16 Blodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
BR112012020481A2 (pt) * 2010-02-22 2017-01-10 Univ Case Western Reserve método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3101382A1 (de) * 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
SU1131507A1 (ru) * 1982-05-28 1984-12-30 Черновицкий Ордена Трудового Красного Знамени Государственный Университет Способ получени инсулина
DE3511269A1 (de) * 1985-04-12 1986-10-09 Veb Berlin-Chemie, Ddr 1199 Berlin Verfahren zur reinigung von insulin
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
TW326394B (en) 1998-02-11
NO942959L (no) 1995-02-14
CA2129763A1 (en) 1995-02-14
YU50494A (sh) 1997-01-08
DE69428860D1 (de) 2001-12-06
ZA945939B (en) 1996-02-08
NO942959D0 (no) 1994-08-09
PT646379E (pt) 2002-03-28
NZ264197A (en) 1997-01-29
CO4230235A1 (es) 1995-10-19
PL177002B1 (pl) 1999-09-30
AU7024794A (en) 1995-02-23
CZ193794A3 (en) 1995-03-15
UA27874C2 (uk) 2000-10-16
PL304600A1 (en) 1995-02-20
JPH07149660A (ja) 1995-06-13
EP0646379B1 (de) 2001-10-31
PE14495A1 (es) 1995-06-02
KR950005324A (ko) 1995-03-20
HUT67853A (en) 1995-05-29
US5534488A (en) 1996-07-09
BR9403204A (pt) 1995-04-18
DK0646379T3 (da) 2001-12-03
AU674975B2 (en) 1997-01-16
PH30757A (en) 1997-10-17
HU9402287D0 (en) 1994-09-28
EP0646379A1 (de) 1995-04-05
CN1109364A (zh) 1995-10-04
ES2164691T3 (es) 2002-03-01
IL110581A0 (en) 1994-11-11
RU2135205C1 (ru) 1999-08-27
DE69428860T2 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
DK0646379T3 (da) Insulinformulering
AU610636B2 (en) Stabilised human protein preparations
ES8101382A1 (es) Un procedimiento para la obtencion de un aglutinante para los tejidos a base de proteinas humanas o animales
GB9108652D0 (en) Immunoreactive compounds
CA2020439A1 (en) Modified biologically active protein
WO1994001006A3 (en) Composition for use as a food or food supplement
CA2015186A1 (en) Nutrient composition
NZ228710A (en) Modified "echistatin" and anti-clotting pharmaceutical composition
AU8188087A (en) Variants of hirudin, their use and their preparation
EP0511903A3 (en) Conjugate of calcitonin and polyethylene glycol
AU2670495A (en) Ifn-beta liquid formulations
AU624079B2 (en) Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives
AU5707090A (en) Hair treatment composition
AU6406590A (en) Porcine lactoferrin amino acid and cdna sequence
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
MD1714G2 (ro) Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
RU95113498A (ru) Линейные или циклические олигопептиды, обладающие сродством к опиоидным рецепторам, фармацевтическая композиция, способ лечения
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
CA2153071A1 (en) Derivatized calcitonins
GR3007486T3 (de)
EP0292302A3 (de) Menschliches Splenin
CA2247998A1 (en) Fragments of cr1 and their use
AU2423488A (en) Pharmaceutical presentation potentializing the cytotrophic effect of animal and/or human sera and/or antitissue antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee